Diffusion Pharmaceuticals

141 articles about Diffusion Pharmaceuticals

• Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care

  11/19/2019

  Chief Scientific Officer Dr. John Gainer to Present at Inaugural Glioblastoma Drug Development Summit

• Diffusion Pharmaceuticals Announces Closing of $4.0 Million Public Offering

  11/15/2019

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) a clinical-stage biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced the closing of its previously announced public offering of an aggregate of 11,428,572 shares of common stock (or common stock equivalents) of the Company

• Diffusion Pharmaceuticals Announces $4.0 Million Public Offering

  11/13/2019

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”), a clinical-stage biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it has priced a public offering of an aggregate of 11,428,572 shares of common stock (or common stock equivalents) of the Company,

• Diffusion Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

  11/11/2019

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today reported financial results for the three and nine months ended September 30, 2019 and provided a business update.

• First Patient Enrolled in Diffusion Pharmaceuticals’ Phase 2 On-Ambulance Clinical Trial with TSC for the Treatment of Stroke

  10/17/2019

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces that the first patient has been enrolled in its Phase 2 on-ambulance study evaluating trans sodium crocetinate (TSC) for the treatment of stroke.

• 

  Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John Mc...

  8/27/2018

  McCain died Saturday after deciding to discontinue treatment for brain cancer. He approached the end of his life in the same manner in which he approached me that day in Raleigh – with the strength of character.

• Diffusion Pharmaceuticals Announces Allowances of Two U.S. Patent Applications

  2/1/2018

  The allowances include claims for both method of use and composition of matter.

• Diffusion Pharmaceuticals Announces First Patient Dosed in Phase III Trial With TSC in Inoperable Glioblastoma Multiforme

  1/30/2018

  The INTACT trial will compare standard of care radiation therapy and chemotherapy plus TSC against SOC alone.

• Abstract Outlining Pre-Hospital Stroke Study With Diffusion Pharmaceuticals’ TSC To Be Presented at the International Stroke Conference

  1/24/2018

  The abstract introduces the design and rationale for the planned Phase 2 PHAST-TSC study.

• Diffusion Pharmaceuticals Announces $12M Underwritten Public Offering

  1/18/2018

  H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

• 

  Why Diffusion Pharma Surged After Its Biotech Showcase Presentation

  1/10/2018

  Shares of Diffusion Pharma shot up more than 40 percent Tuesday after the company provided an overview of the company and its Phase III candidate.

• Diffusion Pharmaceuticals Begins Phase III Clinical Trial With TSC in Glioblastoma Multiforme

  12/27/2017

  The trial will screen 300 patients and enroll 264 in an effort to ensure that results from 236 patients will be available for analysis.

• Diffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity Rule

  11/20/2017

  The Company today announced that it has received notice from Nasdaq stating that the Company complies with the Nasdaq Capital Market Listing Rules requiring minimum stockholders’ equity of $2.5 million.

• Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

  11/13/2017

  We had cash, cash equivalents and a certificate of deposit totaling $11.2 million as of September 30, 2017.

• 

  Diffusion Pharma Receives Final FDA Protocol Guidance for Phase III Clinical Trial with TSC in Pa...

  10/17/2017

  The company expects to begin trial by year-end.

• Diffusion Pharma Names William Hornung Chief Business Officer

  8/23/2017

• Diffusion Pharma Reports Second Quarter 2017 Financial Results And Provides Business Update

  8/15/2017

• Diffusion Pharma Selects Contract Research Organization For Phase III Clinical Trial Of Lead Compound TSC For Inoperable GBM Brain Cancer

  7/31/2017

• Diffusion Pharma Achieves Drug Production Milestone For Planned Phase III Clinical Trial In Inoperable GBM Brain Cancer

  7/20/2017

• Diffusion Pharma Appoints Dr. Robert Ruffolo To Board Of Directors

  7/6/2017